Comparative Effectiveness of Baricitinib Versus Tocilizumab in Hospitalized Patients With COVID-19: A Retrospective Cohort Study of the National Covid Collaborative
Main finding · 28-day mortalityResult — go to the resultOdds ratio 0.91 95% CI 0.85–0.98Authors' conclusion
In this large, diverse cohort of U.S. hospitalized adults with COVID-19, baricitinib was associated with significantly lower 28-day mortality, hospital mortality, shorter hospital length of stay, and less hospital-acquired infections compared with tocilizumab.
Study context
- Population
- Adults hospitalized for COVID-19, US National COVID Cohort Collaborative (N3C), 75 hospitals
- Participants
- 10,661 adults
- Exposure
- Baricitinib vs tocilizumab
- Baricitinibn = 6,229
- Tocilizumabn = 4,432reference
- Outcome
- 28-day mortality
- Follow-up
- 28 days
Methodological detailsmulticentre, propensity-weighted (IPTW), target trial emulation
- Multicentre
- Propensity-weighted (IPTW)
- Target trial emulation
Main finding
As reported in the abstract
Odds ratio
0.91
95% CI 0.85–0.98
Baricitinib vs Tocilizumab
OR 0.91 (95% CI 0.85–0.98)
Observational data: associations, not effects.
Further findings
| Outcome | Estimate | |
|---|---|---|
| Hospital mortalityIPTW-adjusted | OR 0.88 (95% CI 0.82–0.94) | |
| Hospital LOS | IRR 0.92 (95% CI 0.90–0.94) | |
| 0.512Ratio (log scale) |
ICU LOS
- No difference between the two groups
Safety
| Outcome | OR (95% CI) | |
|---|---|---|
| Hospital-acquired infections | 0.86 (0.75–0.99) | |
| 0.512Odds ratio (log scale) |
Original publication
Comparative Effectiveness of Baricitinib Versus Tocilizumab in Hospitalized Patients With COVID-19: A Retrospective Cohort Study of the National Covid Collaborative. Crit Care Med. Published 4 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →